- Home
- PSBD vs FHTX Comparison
PSBD vs FHTX Comparison
Compare PSBD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- FHTX
- Stock Information
- Founded
- PSBD 2009
- FHTX 2015
- Country
- PSBD United States
- FHTX United States
- Employees
- PSBD N/A
- FHTX N/A
- Industry
- PSBD
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- PSBD
- FHTX Health Care
- Exchange
- PSBD Nasdaq
- FHTX Nasdaq
- Market Cap
- PSBD 524.9M
- FHTX 513.7M
- IPO Year
- PSBD 2024
- FHTX 2020
- Fundamental
- Price
- PSBD $15.69
- FHTX $8.01
- Analyst Decision
- PSBD Buy
- FHTX Strong Buy
- Analyst Count
- PSBD 7
- FHTX 5
- Target Price
- PSBD $16.93
- FHTX $16.00
- AVG Volume (30 Days)
- PSBD 24.5K
- FHTX 134.3K
- Earning Date
- PSBD 11-05-2024
- FHTX 11-04-2024
- Dividend Yield
- PSBD 11.92%
- FHTX N/A
- EPS Growth
- PSBD N/A
- FHTX N/A
- EPS
- PSBD N/A
- FHTX N/A
- Revenue
- PSBD N/A
- FHTX $25,515,000.00
- Revenue This Year
- PSBD N/A
- FHTX N/A
- Revenue Next Year
- PSBD N/A
- FHTX $8.77
- P/E Ratio
- PSBD N/A
- FHTX N/A
- Revenue Growth
- PSBD N/A
- FHTX N/A
- 52 Week Low
- PSBD $15.27
- FHTX $2.70
- 52 Week High
- PSBD $17.12
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- PSBD 37.99
- FHTX 44.69
- Support Level
- PSBD $15.63
- FHTX $8.52
- Resistance Level
- PSBD $16.07
- FHTX $9.33
- Average True Range (ATR)
- PSBD 0.22
- FHTX 0.70
- MACD
- PSBD -0.02
- FHTX 0.00
- Stochastic Oscillator
- PSBD 8.87
- FHTX 28.69
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.